

Pembrolizumab KEYNOTE-826

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Serious and disabling adverse effects



Other adjustments



Pembrolizumab KEYNOTE-826

SCORE

CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Gynaecological Malignancies  
Therapeutic Indication: Persistent, recurrent, or metastatic cervical cancer in adults whose tumours express PD-L1 with a CPS  $\geq 1$   
Experimental Arm: Pembrolizumab + ChT with or without bevacizumab  
Control Arm: Placebo + ChT with or without bevacizumab

